Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2022 | Exciting updates in ALL and the value of novel immunotherapies

Sara Ghorashian • 11 Dec 2022

ASH 2022

Acute Lymphoblastic Leukemia Leukemia Antibodies BiTEs Blinatumomab CAR-T

Sara Ghorashian, PhD, MD, FRCP, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, briefly discusses the promise of novel immunotherapies in the treatment of acute lymphoblastic leukemia (ALL), and further highlights now these agents are transforming the field in the frontline and relapsed settings. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Novartis: Honoraria, Speakers Bureau; UCLB: Patents & Royalties.

Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL

Sara Ghorashian • 11 Dec 2022

Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel

Sara Ghorashian • 11 Dec 2022

Managing relapse after CAR-T therapy in ALL

Sara Ghorashian • 12 Jun 2022

The potential of CAR T-cell therapy in combination with antibodies for the treatment of ALL

Sara Ghorashian • 12 Jun 2022

Related Videos

Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens

Christina Peters • 15 Apr 2024

Promising novel agents in AML: menin inhibitors

Mark Levis • 16 Apr 2024

EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation

Valentin Ortiz-Maldonado • 16 Apr 2024

Do all patients require maintenance therapy following alloSCT?

Mark Levis • 16 Apr 2024